ABIONYX Pharma SA (ABNX.PA)
EUR 1.25
(2.46%)
EUR 1.25
(2.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.91 Million EUR | -20.13% |
| 2022 | 8.65 Million EUR | -22.42% |
| 2021 | 11.15 Million EUR | 204.86% |
| 2020 | 3.65 Million EUR | 2.12% |
| 2019 | 3.58 Million EUR | -61.46% |
| 2018 | 9.29 Million EUR | -1.18% |
| 2017 | 9.4 Million EUR | -34.91% |
| 2016 | 14.45 Million EUR | 11.98% |
| 2015 | 12.9 Million EUR | 19.24% |
| 2014 | 10.82 Million EUR | 39.44% |
| 2013 | 7.76 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 6.01 Million EUR | 0.0% |
| 2023 Q1 | 9.03 Million EUR | 4.45% |
| 2023 Q3 | 6.91 Million EUR | -23.53% |
| 2023 Q4 | 6.91 Million EUR | 0.0% |
| 2023 FY | 6.91 Million EUR | -20.13% |
| 2023 Q2 | 9.03 Million EUR | 0.0% |
| 2022 Q2 | 9.53 Million EUR | 0.0% |
| 2022 Q3 | 8.65 Million EUR | -9.23% |
| 2022 FY | 8.65 Million EUR | -22.42% |
| 2022 Q1 | 9.53 Million EUR | -14.53% |
| 2022 Q4 | 8.65 Million EUR | 0.0% |
| 2021 Q4 | 11.15 Million EUR | 0.0% |
| 2021 FY | 11.15 Million EUR | 204.86% |
| 2021 Q3 | 11.15 Million EUR | 257.53% |
| 2021 Q2 | 3.12 Million EUR | 0.0% |
| 2021 Q1 | 3.12 Million EUR | -14.73% |
| 2020 Q1 | 3.4 Million EUR | -4.91% |
| 2020 Q3 | 3.59 Million EUR | 4.26% |
| 2020 Q4 | 3.65 Million EUR | 1.7% |
| 2020 Q2 | 3.45 Million EUR | 1.29% |
| 2020 FY | 3.65 Million EUR | 2.12% |
| 2019 Q4 | 3.58 Million EUR | 0.0% |
| 2019 Q3 | 3.58 Million EUR | -10.51% |
| 2019 Q2 | 4 Million EUR | 0.0% |
| 2019 Q1 | 4 Million EUR | -56.94% |
| 2019 FY | 3.58 Million EUR | -61.46% |
| 2018 FY | 9.29 Million EUR | -1.18% |
| 2018 Q4 | 9.29 Million EUR | 0.01% |
| 2018 Q3 | 9.29 Million EUR | -0.17% |
| 2018 Q2 | 9.31 Million EUR | 0.0% |
| 2018 Q1 | 9.31 Million EUR | -1.02% |
| 2017 Q3 | 9.4 Million EUR | 11.6% |
| 2017 Q2 | 8.43 Million EUR | 0.0% |
| 2017 Q1 | 8.43 Million EUR | -41.67% |
| 2017 FY | 9.4 Million EUR | -34.91% |
| 2017 Q4 | 9.4 Million EUR | 0.0% |
| 2016 Q2 | 15.13 Million EUR | 0.0% |
| 2016 FY | 14.45 Million EUR | 11.98% |
| 2016 Q1 | 15.13 Million EUR | 17.24% |
| 2016 Q3 | 14.45 Million EUR | -4.48% |
| 2016 Q4 | 14.45 Million EUR | 0.0% |
| 2015 Q3 | 12.9 Million EUR | 16.22% |
| 2015 Q1 | 4.41 Million EUR | -59.19% |
| 2015 Q4 | 12.9 Million EUR | -0.01% |
| 2015 FY | 12.9 Million EUR | 19.24% |
| 2015 Q2 | 11.1 Million EUR | 151.4% |
| 2014 FY | 10.82 Million EUR | 39.44% |
| 2014 Q3 | 10.82 Million EUR | 0.0% |
| 2014 Q4 | 10.82 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 FY | 7.76 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIVAX Société Anonyme | 131.05 Million EUR | 94.726% |
| Adocia SA | 31.87 Million EUR | 78.312% |
| Aelis Farma SA | 13.08 Million EUR | 47.156% |
| Biophytis S.A. | 15.84 Million EUR | 56.388% |
| Advicenne S.A. | 24.37 Million EUR | 71.645% |
| genOway Société anonyme | 14.45 Million EUR | 52.198% |
| IntegraGen SA | 5.97 Million EUR | -15.589% |
| Medesis Pharma S.A. | 6.42 Million EUR | -7.56% |
| Neovacs S.A. | 3.71 Million EUR | -86.201% |
| NFL Biosciences SA | 3.62 Million EUR | -90.903% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -1.912% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -108.815% |
| Sensorion SA | 13.22 Million EUR | 47.744% |
| Theranexus Société Anonyme | 5.01 Million EUR | -37.794% |
| TME Pharma N.V. | 2.78 Million EUR | -148.187% |
| Valbiotis SA | 13.7 Million EUR | 49.577% |
| TheraVet SA | 1.48 Million EUR | -365.457% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 66.23% |
| argenx SE | 402.79 Million EUR | 98.284% |
| BioSenic S.A. | 32.26 Million EUR | 78.577% |
| Celyad Oncology SA | 9.97 Million EUR | 30.728% |
| DBV Technologies S.A. | 38.74 Million USD | 82.16% |
| Galapagos NV | 1.56 Billion EUR | 99.557% |
| Genfit S.A. | 105.92 Million EUR | 93.474% |
| GeNeuro SA | 20.13 Million EUR | 65.68% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | 19.74% |
| Innate Pharma S.A. | 132.29 Million EUR | 94.775% |
| Inventiva S.A. | 101.59 Million EUR | 93.196% |
| MaaT Pharma SA | 22.46 Million EUR | 69.232% |
| MedinCell S.A. | 77.77 Million EUR | 91.112% |
| Nanobiotix S.A. | 95.74 Million EUR | 92.78% |
| Onward Medical N.V. | 25.69 Million EUR | 73.103% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 72.49% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 88.3% |
| Oxurion NV | 19.73 Million EUR | 64.978% |
| Pharming Group N.V. | 228.28 Million EUR | 96.972% |
| Poxel S.A. | 53.9 Million EUR | 87.176% |
| GenSight Biologics S.A. | 34.72 Million EUR | 80.096% |
| Transgene SA | 26.51 Million EUR | 73.934% |
| Financière de Tubize SA | 123.65 Million EUR | 94.41% |
| UCB SA | 6.56 Billion EUR | 99.895% |
| Valneva SE | 341.14 Million EUR | 97.974% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -52.012% |